By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Daiichi Sankyo Company, Ltd. 

3-5-1, Nihonbashi-honcho

Chuo-ku  Tokyo  103-8426  Japan
Phone: +81-3-6225-1111 Fax:


SEARCH JOBS

Daiichi Sankyo is focused on the discovery and development of novel oncology agents with the goal of delivering first-in-class and best-in-class treatments that address unmet medical needs. The oncology pipeline of Daiichi Sankyo continues to grow and currently includes both small molecules and monoclonal antibodies with novel targets in both solid and hematological cancers.

YEAR FOUNDED:

1899

LEADERSHIP:

CEO: Joji Nakayama

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

All Products


Key Statistics


Email:
Ownership: Private

Web Site: Daiichi Sankyo
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
Inovalon Announces Agreement With Daiichi Sankyo To Support Outcomes-Based Contracting 9/21/2017 8:12:41 AM
MD Anderson Cancer Center And Daiichi Sankyo Enter Research Collaboration To Accelerate Development Of Acute Myeloid Leukemia Therapies 9/14/2017 11:10:23 AM
Daiichi Sankyo Presents New Data For DS-8201 In Multiple HER2-Expressing Solid Tumors At European Society For Medical Oncology (ESMO) 2017 Congress 9/11/2017 7:48:41 AM
Sanford Burnham Prebys Medical Discovery Institute And Daiichi Sankyo Announce Enrollment Of First Subject In A Phase I Clinical Trial Of DS-1211 In Healthy Volunteers 9/6/2017 6:42:17 AM
Daiichi Sankyo Denies AstraZeneca PLC (AZN) Courtship 8/31/2017 12:56:31 PM
Daiichi Sankyo Showcases New Insights On Multiple Oncology Compounds At The European Society For Medical Oncology (ESMO) 2017 Congress 8/31/2017 7:54:47 AM
Daiichi Sankyo Announces Positive Top-Line Results From Phase III Clinical Trial Evaluating Mirogabalin In Diabetic Peripheral Neuropathic Pain 8/31/2017 7:26:51 AM
Daiichi Sankyo Terminates $650 Million Deal With This U.S. Pharma 8/31/2017 6:16:27 AM
Bristol-Myers Squibb (BMY) And Daiichi Sankyo Announce Research Collaboration To Evaluate Opdivo (Nivolumab) And DS-8201 In HER2-Expressing Breast And Bladder Cancers 8/29/2017 8:38:22 AM
Daiichi Sankyo Initiates Pivotal Phase II Study Of DS-8201 In Patients With HER2-Positive Metastatic Breast Cancer 8/29/2017 8:27:45 AM
123456789
//-->